Advances in GBA-associated Parkinson's disease - Pathology, presentation and therapies

Neurochemistry International

Volumn 93, Issue , 2016, Pages 6-25

  Barkhuizen, Melinda ^a,b   Anderson, David G ^c   Grobler, Anne F ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c University of the Witwatersrand   (South Africa)

Author keywords

Gaucher disease; Glucocerebrosidase; LIMP 2; Parkinson's disease; Synuclein

Indexed keywords

ACETYLCYSTEINE; ALGLUCERASE; ALPHA SYNUCLEIN; AMBROXOL; CERAMIDE; CHAPERONE; CHEMOTACTIC FACTOR; CHOLINESTERASE INHIBITOR; CLONAZEPAM; DOPAMINE TRANSPORTER; ELIGLUSTAT; ESZOPICLONE; GLUCOSYLCERAMIDASE; GLYCOSIDASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMIGLUCERASE; ISOFAGOMINE; LEVODOPA; LYSOSOMAL INTEGRAL MEMBRANE PROTEIN TYPE 2; LYSOSOME ENZYME; MELATONIN; MEMBRANE PROTEIN; METAL; MIGLUSTAT; PARKIN; POTASSIUM CHLORIDE; QUETIAPINE; REACTIVE OXYGEN METABOLITE; TALIGLUCERASE ALFA; UNCLASSIFIED DRUG; VELAGLUCERASE ALFA;

AUTONOMIC DYSFUNCTION; AUTONOMIC NERVOUS SYSTEM; BRAIN; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CYTOLOGY; DEMENTIA; DEPRESSION; DOPPLER ECHOGRAPHY; DYSAUTONOMIA; ENZYME REPLACEMENT; EYE DISEASE; GAUCHER DISEASE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; MENTAL DISEASE; MOLECULE; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; ONSET AGE; PARKINSON DISEASE; PARKINSONISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REM SLEEP; REVIEW; RISK FACTOR; SCREENING TEST; SLEEP DISORDER; SMELLING DISORDER; ADULT; GENETICS; MUTATION; PATHOLOGY;

ADULT; GLUCOSYLCERAMIDASE; HUMANS; MUTATION; PARKINSON DISEASE;

EID: 84958772799     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2015.12.004     Document Type: Review

References (201)

1. S.K. Abbott, H. Li, S.S. Muñoz, B. Knoch, M. Batterham, K.E. Murphy, G.M. Halliday, and B. Garner Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease Mov. Disord. 29 2014 518 526
2. N. Abramycheva, E. Fedotova, M. Stepanova, S. Klyushnikov, V. Poleshchuk, and S. Illarioshkin Extensive screening of GBA gene in Russian patients with Parkinson's disease Mov. Disord. 29 2014 S43 S44
3. E. Aflaki, B.K. Stubblefield, E. Maniwang, G. Lopez, N. Moaven, E. Goldin, J. Marugan, S. Patnaik, A. Dutra, and N. Southall Macrophage models of gaucher disease for evaluating disease pathogenesis and candidate drugs Sci. Transl. Med. 6 2014 240 273
4. F. Agosta, V.S. Kostic, K. Davidovic, N. Kresojević, L. Sarro, M. Svetel, I. Stanković, G. Comi, C. Klein, and M. Filippi White matter abnormalities in Parkinson's disease patients with glucocerebrosidase gene mutations Mov. Disord. 28 2013 772 778
5. A. Akpalu, D. Rusconi, R. Asselta, P. Adjei, F. Sarfo, M. Cham, M. Amboni, M. Fabbri, S. Duga, and G. Pezzoli Genetics of Parkinson's disease in Ghana: shall we look for new genes? Mov. Disord. 29 2014 S44-S44
6. R.N. Alcalay, T. Dinur, T. Quinn, K. Sakanaka, O. Levy, C. Waters, S. Fahn, T. Dorovski, W.K. Chung, and M. Pauciulo Comparison of parkinson risk in ashkenazi jewish patients with gaucher disease and GBA heterozygotes JAMA Neurol. 71 2014 752 757
7. R.N. Alcalay, O.A. Levy, C.C. Waters, S. Fahn, B. Ford, S.-H. Kuo, P. Mazzoni, M.W. Pauciulo, W.C. Nichols, and Z. Gan-Or Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations Neurology 84 2015 S7-003
8. P. Alfonso, V. Andreu, A. Pino-Angeles, M.I. García-Moreno, F. Sánchez-Jiménez, M. Pocovi, C.O. Mellet, J.M. García-Fernández, and P. Giraldo Bicyclic derivatives of L-idonojirimycin as pharmacological chaperones for neuronopathic forms of Gaucher disease Mol. Genet. Metabol. 111 2014 S18 S19
9. Ö. Altintaş, P. Işeri, B. Özkan, and Y. Çaʇlar Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease Doc. Ophthalmol. 116 2008 137 146
10. L. Alvarez-Erviti, Y. Seow, A.H. Schapira, C. Gardiner, I.L. Sargent, M.J. Wood, and J.M. Cooper Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission Neurobiol. Dis. 42 2011 360 367
11. G. Ambrosi, C. Ghezzi, R. Zangaglia, G. Levandis, C. Pacchetti, and F. Blandini Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells Neurobiol. Dis. 82 2015 235 242
12. C. Ankleshwaria, J. Sheth, M. Mistri, A. Bavdekar, S. Nampoothiri, S. Gupta, and F. Sheth Identification of novel mutations in glucocerebrosidase (GBA) gene in Indian patients with gaucher disease (GD) Mol. Cytogenet. 7 2014 P52
13. C.A. Antoniades, N. Demeyere, C. Kennard, G.W. Humphreys, and M.T. Hu Antisaccades and executive dysfunction in early drug-naive Parkinson's disease: the discovery study Mov. Disord. 30 2015 843 847
14. O. Arancio, and M.V. Chao Neurotrophins, synaptic plasticity and dementia Curr. Opin. Neurobiol. 17 2007 325 330
15. N. Archibald, M. Clarke, U. Mosimann, and D. Burn Retinal thickness in Parkinson's disease Park. Relat. Disord. 17 2011 431 436
16. R. Asselta, V. Rimoldi, C. Siri, R. Cilia, I. Guella, S. Tesei, G. Soldà, G. Pezzoli, S. Duga, and S. Goldwurm Glucocerebrosidase mutations in primary parkinsonism Park. Relat. Disord. 20 2014 1215 1220
17. O. Awad, C. Sarkar, L.M. Panicker, D. Miller, X. Zeng, J.A. Sgambato, M.M. Lipinski, and R.A. Feldman Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSCs-derived neuronal cells Hum. Mol. Genet. 20 2015 5775 5788
18. E.-J. Bae, N.-Y. Yang, M. Song, C.S. Lee, J.S. Lee, B.C. Jung, H.-J. Lee, S. Kim, E. Masliah, and S.P. Sardi Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein Nat. Commun. 5 2014 4755
19. E.-J. Bae, N.Y. Yang, C. Lee, H.-J. Lee, S. Kim, S.P. Sardi, and S.-J. Lee Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation Exp. Mol. Med. 47 2015 e153
20. M. Balwani, L. Fuerstman, R. Kornreich, L. Edelmann, and R.J. Desnick Type 1 Gaucher disease: significant disease manifestations in "asymptomatic" homozygotes Arch. Intern. Med. 170 2010 1463 1469
21. M. Barrett, J. Hagenah, V. Dhawan, S. Peng, K. Stanley, D. Raymond, A. Deik, S. Gross, N. Schreiber-Agus, and A. Mirelman Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease Park. Relat. Disord. 19 2013 186 191
22. M. Barrett, V. Shanker, W. Severt, D. Raymond, S. Gross, N. Schreiber-Agus, R. Kornreich, L. Ozelius, S. Bressman, and R. Saunders-Pullman Cognitive and antipsychotic medication use in monoallelic GBA-related parkinson disease JIMD Rep. 16 2014 31 38
23. M. Beavan, A. McNeill, C. Proukakis, D.A. Hughes, A. Mehta, and A. Schapira Evolution of prodromal clinical markers of parkinson disease in a GBA Mutation-Positive cohort JAMA Neurol. 72 2015 201 208
24. I. Bendikov-Bar, G. Maor, M. Filocamo, and M. Horowitz Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase Blood Cells Mol. Dis. 50 2013 141 145
25. I. Bendikov-Bar, D. Rapaport, S. Larisch, and M. Horowitz Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS Orphanet J. Rare Dis. 9 2014 86
26. I. Bendikov-Bar, I. Ron, M. Filocamo, and M. Horowitz Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant Blood Cells Mol. Dis. 46 2011 4 10
27. W. Benko, M. Ries, E.A. Wiggs, R.O. Brady, R. Schiffmann, and E.J. FitzGibbon The saccadic and neurological deficits in type 3 Gaucher disease PLoS One 6 2011 e22410
28. B.P. Boot, B.F. Boeve, R.O. Roberts, T.J. Ferman, Y.E. Geda, V.S. Pankratz, R.J. Ivnik, G.E. Smith, E. McDade, and H. Christianson Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study Ann. Neurol. 71 2012 49 56
29. T. Böttcher, A. Rolfs, B. Meyer, A. Grossmann, D. Berg, P. Kropp, R. Benecke, and U. Walter Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease J. Neurol. 260 2013 2523 2531
30. K. Brockmann, R. Hilker, U. Pilatus, S. Baudrexel, K. Srulijes, J. Magerkurth, A.-K. Hauser, C. Schulte, I. Csoti, and C.D. Merten GBA-associated PD Neurodegeneration, altered membrane metabolism, and lack of energy failure Neurology 79 2012 213 220
31. K. Brockmann, K. Srulijes, S. Pflederer, A.K. Hauser, C. Schulte, W. Maetzler, T. Gasser, and D. Berg GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study Mov. Disord. 30 2014 407 411
32. D.G. Burke, A.A. Rahim, S.N. Waddington, S. Karlsson, I. Enquist, K. Bhatia, A. Mehta, A. Vellodi, and S. Heales Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes J. Inherit. Metabol. Dis. 36 2013 869 872
33. E. Cassinerio, G. Graziadei, and E. Poggiali Gaucher disease: a diagnostic challenge for internists Eur. J. Intern. Med. 25 2014 117 124
34. L.M. Chahine, J. Qiang, E. Ashbridge, J. Minger, D. Yearout, S. Horn, A. Colcher, H.I. Hurtig, V.M. Lee, and V.M. Van Deerlin Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations JAMA Neurol. 70 2013 852 858
35. K. Chaudhuri, D.G. Healy, and A.H. Schapira Non-motor symptoms of Parkinson's disease: diagnosis and management Lancet Neurol. 5 2006 235 245
36. R.G. Chaves, L. Pereira, F. de Araújo, R. Rozenberg, M. Carvalho, J. Coelho, K. Michelin-Tirelli, M. Chaves, and G. Cavalcanti Consanguinity and founder effect for Gaucher disease mutation G377S in a population from Tabuleiro do Norte, Northeastern Brazil Clin. Genet. 88 2014 391 395
37. D. Chiasserini, S. Paciotti, P. Eusebi, E. Persichetti, A. Tasegian, M. Kurzawa-Akanbi, P.F. Chinnery, C.M. Morris, P. Calabresi, and L. Parnetti Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies Mol. Neurodegener. 10 2015 15
38. Y. Chu, H. Dodiya, P. Aebischer, C.W. Olanow, and J.H. Kordower Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions Neurobiol. Dis. 35 2009 385 398
39. L.N. Clark, R. Chan, R. Cheng, X. Liu, N. Park, N. Parmalee, S. Kisselev, E. Cortes, P.A. Torres, and G.M. Pastores Gene-Wise Association of Variants in Four Lysosomal Storage Disorder Genes in Neuropathologically Confirmed Lewy Body Disease PLoS One 10 2015 e0125204
40. L.N. Clark, L.A. Kartsaklis, R.W. Gilbert, B. Dorado, B.M. Ross, S. Kisselev, M. Verbitsky, H. Mejia-Santana, L.J. Cote, and H. Andrews Association of glucocerebrosidase mutations with Dementia with Lewy Bodies Arch. Neurol. 66 2009 578 583
41. L.N. Clark, S. Kisselev, N. Park, B. Ross, M. Verbitsky, E. Rios, R.N. Alcalay, J.H. Lee, and E.D. Louis Mutations in the Parkinson's disease genes, Leucine Rich Repeat Kinase 2 (LRRK2) and Glucocerebrosidase (GBA), are not associated with essential tremor Park. Relat. Disord. 16 2010 132 135
42. Y. Compta, L. Parkkinen, P. Kempster, M. Selikhova, T. Lashley, J.L. Holton, A.J. Lees, and T. Revesz The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia Neurodegener. Dis. 13 2014 154 156
43. O. Corti, S. Lesage, and A. Brice What genetics tells us about the causes and mechanisms of Parkinson's disease Physiol. Rev. 91 2011 1161 1218
44. D. Crosiers, A. Verstraeten, E. Wauters, B. Pickut, E. Elinck, E. Corsmit, M. Mattheijssens, K. Peeters, P. De Deyn, and C. Van Broeckhoven Glucerebrosidase mutations: an important genetic risk factor in Flanders-Belgian PD patients associated with a more severe disease phenotype Mov. Disord. 29 2014 S49-S49
45. M. Dahl, A. Doyle, K. Olsson, J.-E. Månsson, A.R. Marques, M. Mirzaian, J.M. Aerts, M. Ehinger, M. Rothe, and U. Modlich Lentiviral gene therapy using cellular promoters cures type 1 gaucher disease in mice Mol. Ther. 23 2015 285
46. N. Dasgupta, Y.-h. Xu, R. Li, Y. Peng, M.K. Pandey, S.L. Tinch, B. Liou, V. Inskeep, W. Zhang, and K.D. Setchell Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model Hum. Mol. Genet. 24 2015 7031 7048
47. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 2003 889 909
48. M. de la Mata, D. Cotán, M. Oropesa-Ávila, J. Garrido-Maraver, M.D. Cordero, M.V. Paz, A.D. Pavón, E. Alcocer-Gómez, I. de Lavera, and P. Ybot-González Pharmacological chaperones and Coenzyme Q10 treatment improves mutant β-glucocerebrosidase activity and mitochondrial function in neuronopathic forms of gaucher disease Sci. Rep. 5 2015 10903
49. G. Dermentzaki, E. Dimitriou, M. Xilouri, H. Michelakakis, and L. Stefanis Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells PLoS One 8 2013 e60674
50. N.J. Diederich, and D.J. McIntyre Sleep disorders in Parkinson's disease: many causes, few therapeutic options J. Neurol. Sci. 314 2012 12 19
51. D.A. Drachman The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer's disease Alzheimer's Dementia 10 2014 372 380
52. R. Duran, N.E. Mencacci, A.V. Angeli, M. Shoai, E. Deas, H. Houlden, A. Mehta, D. Hughes, T.M. Cox, and P. Deegan The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease Mov. Disord. 28 2013 232 236
53. E.-L. Eskelinen Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy Mol. Aspects Med. 27 2006 495 502
54. M.J. Farrer, L.N. Williams, A.A. Algom, J. Kachergus, M.M. Hulihan, O.A. Ross, A. Rajput, S. Papapetropoulos, D.C. Mash, and D.W. Dickson Glucosidase-beta variations and Lewy body disorders Park. Relat. Disord. 15 2009 414 416
55. I. Fishbein, Y.-M. Kuo, B.I. Giasson, and R.L. Nussbaum Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation Brain 137 2014 3235 3247
56. Z. Gan-Or, I. Amshalom, A. Bar-Shira, M. Gana-Weisz, A. Mirelman, K. Marder, S. Bressman, N. Giladi, and A. Orr-Urtreger The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease J. Neurol. 262 2015 2443 2447
57. Z. Gan-Or, I. Amshalom, L.L. Kilarski, A. Bar-Shira, M. Gana-Weisz, A. Mirelman, K. Marder, S. Bressman, N. Giladi, and A. Orr-Urtreger Differential effects of severe vs mild GBA mutations on Parkinson disease Neurology 84 2015 880 887
58. Z. Gan-Or, N. Giladi, U. Rozovski, C. Shifrin, S. Rosner, T. Gurevich, A. Bar-Shira, and A. Orr-Urtreger Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset Neurology 70 2008 2277 2283
59. P. Garcia-Reitböck, O. Anichtchik, A. Bellucci, M. Iovino, C. Ballini, E. Fineberg, B. Ghetti, L. Della Corte, P. Spano, and G.K. Tofaris SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease Brain 133 2010 2032 2044
60. M.E. Gegg, D. Burke, S.J. Heales, J.M. Cooper, J. Hardy, N.W. Wood, and A.H. Schapira Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains Ann. Neurol. 72 2012 455 463
61. M.E. Gegg, L. Sweet, B.H. Wang, L.S. Shihabuddin, S.P. Sardi, and A.H. Schapira No evidence for substrate accumulation in Parkinson brains with GBA mutations Mov. Disord. 30 2015 1085 1089
62. E.I. Ginns, S.K.-K. Mak, N. Ko, J. Karlgren, S. Akbarian, V.P. Chou, Y. Guo, A. Lim, S. Samuelsson, and M.L. LaMarca Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction Mol. Genet. Metabol. 111 2014 152 162
63. A. Glickman, O. Bodamer, B. Johnson, W. Nichols, M. Pullman, R. Ortega, B. Johannes, D. Raymond, L. Ozelius, and J. Bielawski Peripheral β-glucocerebrosidase enzyme activity and lipidomics in β-glucocerebrosidase (GBA1) mutation Parkinson disease (P2. 149) Neurology 84 P2 2015 149
64. O. Goker-Alpan, G. Lopez, J. Vithayathil, J. Davis, M. Hallett, and E. Sidransky The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations Arch. Neurol. 65 2008 1353 1357
65. O. Goker-Alpan, J.C. Masdeu, P.D. Kohn, A. Ianni, G. Lopez, C. Groden, M.C. Chapman, B. Cropp, D.P. Eisenberg, and E.D. Maniwang The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow Brain 135 2012 2440 2448
66. O. Goker-Alpan, R. Schiffmann, M. LaMarca, R. Nussbaum, A. McInerney-Leo, and E. Sidransky Parkinsonism among Gaucher disease carriers J. Med. Genet. 41 2004 937 940
67. V.M. Gonçalves, V. D'Almeida, K.B. Müller, F. Real, and R.A. Mortara Lysosomal integral membrane protein 2 (LIMP-2) restricts the invasion of Trypanosoma cruzi extracellular amastigotes through the activity of the lysosomal enzyme β-glucocerebrosidase Microbes Infect. 16 2014 253 260
68. M. Gorges, H.-P. Müller, D. Lulé, E.H. Pinkhardt, A.C. Ludolph, J. Kassubek, and L. Consortium The association between alterations of eye movement control and cerebral intrinsic functional connectivity in Parkinson's disease Brain Imaging Behav. 2015 1 13
69. M.O. Grimm, B. Hundsdörfer, S. Groesgen, J. Mett, V.C. Zimmer, C.P. Stahlmann, V.J. Haupenthal, T.L. Rothhaar, J. Lehmann, and A. Paetzold PS dependent APP cleavage regulates glucosylceramide synthase and is affected in Alzheimer's disease Cell. Physiol. Biochem. 34 2014 92 110
70. J.M. Gruschus Did α-synuclein and glucocerebrosidase coevolve? implications for Parkinson's disease PLoS One 10 2015 e0133863
71. J.M. Gruschus, Z. Jiang, T.L. Yap, S.A. Hill, A. Grishaev, G. Piszczek, E. Sidransky, and J.C. Lee Dissociation of glucocerebrosidase dimer in solution by its co-factor, saposin C Biochem. Biophys. Res. Commun. 457 2015 561 566
72. F. Han, D.A. Grimes, F. Li, T. Wang, Z. Yu, N. Song, S. Wu, L. Racacho, and D.E. Bulman Mutations in the glucocerebrosidase gene are common in patients with Parkinson's disease from Eastern Canada Int. J. Neurosci. 2015 1 19
73. M.J. Holmay, M. Terpstra, L.D. Coles, U. Mishra, M. Ahlskog, G. Öz, J.C. Cloyd, and P.J. Tuite N-acetylcysteine boosts brain and blood glutathione in gaucher and Parkinson diseases Clin. Neuropharmacol. 36 2013 103 106
74. F. Hopfner, E.C. Schulte, B. Mollenhauer, B. Bereznai, F. Knauf, P. Lichtner, A. Zimprich, D. Haubenberger, W. Pirker, and T. Brücke The role of SCARB2 as susceptibility factor in Parkinson's disease Mov. Disord. 28 2013 538 540
75. K.S. Hruska, M.E. LaMarca, C.R. Scott, and E. Sidransky Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA) Hum. Mutat. 29 2008 567 583
76. R. Inzelberg, J.A. Ramirez, P. Nisipeanu, and A. Ophir Retinal nerve fiber layer thinning in Parkinson disease Vis. Res. 44 2004 2793 2797
77. A. Iranzo, E. Tolosa, E. Gelpi, J.L. Molinuevo, F. Valldeoriola, M. Serradell, R. Sanchez-Valle, I. Vilaseca, F. Lomeña, and D. Vilas Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study Lancet Neurol. 12 2013 443 453
78. A. Jack, D. Amato, G. Morris, and F.Y. Choy Two novel mutations in glucocerebrosidase, C23W and IVS7-1 G>A, identified in type 1 Gaucher patients heterozygous for N370S Gene 538 2014 84 87
79. Z. Jamrozik, A. Lugowska, D. Koziorowski, A. Friedman, J. Slawek, P. Janik, A. Potulska-Chromik, M. Kuzma-Kozakiewicz, A. Wisniewska, and M. Szubiga Mutations L444P and N370S in the GBA gene in polish patients with early and later onset Parkinson's disease Mov. Disord. 29 2014 S53-S53
80. Z. Jamrozik, A. Lugowska, J. Slawek, and H. Kwiecinski Glucocerebrosidase mutations p. L444P and p. N370S are not associated with multisystem atrophy, progressive supranuclear palsy and corticobasal degeneration in polish patients J. Neurol. 257 2010 459 460
81. M. Jankovic, V. Dobricic, N. Kresojevic, M. Zarkovic, M. Svetel, I. Novakovic, and V. Kostic Glucocerebrosidase-associated Parkinson's disease in Serbian population: from epidemiological studies to clinical implementation Mov. Disord. 29 2014 S53-S53
82. H. Kang, and J.-H. Shin Repression of rRNA transcription by PARIS contributes to Parkinson's disease Neurobiol. Dis. 73 2015 220 228
83. M. Keatinge, H. Bui, A. Menke, Y.-C. Chen, A.M. Sokol, Q. Bai, F. Ellett, M. Da Costa, D. Burke, and M. Gegg Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death Hum. Mol. Genet. 24 2015 6640 6652
84. M. Keatinge, M. DaCosta, A. Menke, Y.-C. Chen, H.H. Bui, M. O'Neill, and O. Bandmann Zebrafish as a model of glucocerebrosidase 1 (GBA1) deficiency J. Neurol. Neurosurg. Psychiatry 86 2015 e4-e4
85. B.S. Kilpatrick, J. Magalhaes, M.S. Beavan, A. McNeill, M.E. Gegg, M.W. Cleeter, D. Bloor-Young, G.C. Churchill, M.R. Duchen, and A.H. Schapira Endoplasmic reticulum and lysosomal Ca 2+ stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts Cell Calcium 2015
86. K. Kitatani, M. Wada, D. Perry, T. Usui, Y. Sun, L.M. Obeid, N. Yaegashi, G.A. Grabowski, and Y.A. Hannun Activation of p38 mitogen-activated protein kinase in Gaucher's disease PLoS One 10 2015 e0136633
87. S.M. Kong, B.K. Chan, J.-S. Park, K.J. Hill, J.B. Aitken, L. Cottle, H. Farghaian, A.R. Cole, P.A. Lay, and C.M. Sue Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes Hum. Mol. Genet. 23 2014 2816 2833
88. H.G. Körschen, Y. Yildiz, D.N. Raju, S. Schonauer, W. Bönigk, V. Jansen, E. Kremmer, U.B. Kaupp, and D. Wachten The non-lysosomal β-glucosidase GBA2 is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi J. Biol. Chem. 288 2013 3381 3393
89. H. Kozlowski, M. Luczkowski, M. Remelli, and D. Valensin Copper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases) Coord. Chem. Rev. 256 2012 2129 2141
90. N. Kresojević, M. Mijajlović, S. Perić, A. Pavlović, M. Svetel, M. Janković, V. Dobričić, I. Novaković, M.B. Lakočević, and C. Klein Transcranial sonography in patients with Parkinson's disease with glucocerebrosidase mutations Park. Relat. Disord. 19 2013 431 435
91. K. Kumar, A. Ramirez, A. Göbel, N. Kresojević, M. Svetel, K. Lohmann, C. M Sue, A. Rolfs, J. Mazzulli, and R. Alcalay Glucocerebrosidase mutations in a Serbian Parkinson's disease population Eur. J. Neurol. 20 2013 402 405
92. M.M. Kurtis, C. Rodriguez-Blazquez, P. Martinez-Martin, and E. Group Relationship between sleep disorders and other non-motor symptoms in Parkinson's disease Park. Relat. Disord. 19 2013 1152 1155
93. R. Lachmann Miglustat. Oxford GlycoSciences/Actelion Curr. Opin. Investig. Drugs 4 2003 472 479
94. R.H. Lachmann Enzyme replacement therapy for lysosomal storage diseases Curr. Opin. Pediatr. 23 2011 588 593
95. S.D. Larsen, M.W. Wilson, A. Abe, L. Shu, C.H. George, P. Kirchhoff, H.H. Showalter, J. Xiang, R.F. Keep, and J.A. Shayman Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain J. Lipid Res. 53 2012 282 291
96. Y. Li, T. Sekine, M. Funayama, L. Li, H. Yoshino, K. Nishioka, H. Tomiyama, and N. Hattori Clinicogenetic study of GBA mutations in patients with familial Parkinson's disease Neurobiol. Aging 35 2014 933 935
97. B. Liou, W.D. Haffey, K.D. Greis, and G.A. Grabowski The LIMP-2/SCARB2 binding motif on acid β-Glucosidase basic and applifed implications for Gaucher disease and associated neurodegenerative diseases J. Biol. Chem. 289 2014 30063 30074
98. G. Liu, M. Chen, N. Mi, W. Yang, X. Li, P. Wang, N. Yin, Y. Li, F. Yue, and P. Chan Increased oligomerization and phosphorylation of α-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains Neurobiol. Aging 36 2015 2649 2659
99. J. Liu, and H.X. Zhang Significant study of population stratification, sensitivity analysis and trim and fill analyses on GBA mutation and parkinson's disease Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 165 2014 96 102
100. M.R. MacAskill, C.F. Graham, T.L. Pitcher, D.J. Myall, L. Livingston, S. van Stockum, J.C. Dalrymple-Alford, and T.J. Anderson The influence of motor and cognitive impairment upon visually-guided saccades in Parkinson's disease Neuropsychologia 50 2012 3338 3347
101. M. Machaczka, R. Hast, I. Dahlman, R. Lerner, M. Klimkowska, M. Engvall, and H. Hägglund Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution Upsala J. Med. Sci. 117 2012 28 34
102. M. Machaczka, and M. Klimkowska Novel heterozygous c. 798C> G and c. 1040T> G mutations in the GBA1 gene are associated with a severe phenotype of Gaucher disease type 1 Ann. Hematol. 2014 1 3
103. G.H. Maegawa, M.B. Tropak, J.D. Buttner, B.A. Rigat, M. Fuller, D. Pandit, L. Tang, G.J. Kornhaber, Y. Hamuro, and J.T. Clarke Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease J. Biol. Chem. 284 2009 23502 23516
104. M. Malec-Litwinowicz, M. Rudzińska, M. Szubiga, M. Michalski, T. Tomaszewski, and A. Szczudlik Cognitive impairment in carriers of glucocerebrosidase gene mutation in Parkinson disease patients Neurol. i Neurochir. Pol. 48 2014 258 261
105. E. Malini, S. Grossi, M. Deganuto, C. Rosano, R. Parini, S. Dominisini, R. Cariati, S. Zampieri, B. Bembi, and M. Filocamo Functional analysis of 11 novel GBA alleles Eur. J. Hum. Genet. 22 2014 511 516
106. E. Maniwang, N. Tayebi, and E. Sidransky Is Parkinson disease associated with lysosomal integral membrane protein type-2?: challenges in interpreting association data Mol. Genet. Metabol. 108 2013 269 271
107. S. Mattošová, J. Chandoga, A. Hlavatá, J. Saligová, and D. Maceková Spectrum of GBA mutations in patients with Gaucher disease from Slovakia: identification of five novel mutations Israel Med. Assoc. J. IMAJ 17 2015 166 170
108. J.R. Mazzulli, Y.-H. Xu, Y. Sun, A.L. Knight, P.J. McLean, G.A. Caldwell, E. Sidransky, G.A. Grabowski, and D. Krainc Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies Cell 146 2011 37 52
109. A. McNeill, R. Duran, C. Proukakis, J. Bras, D. Hughes, A. Mehta, J. Hardy, N.W. Wood, and A.H. Schapira Hyposmia and cognitive impairment in Gaucher disease patients and carriers Mov. Disord. 27 2012 526 532
110. A. McNeill, J. Magalhaes, C. Shen, K.-Y. Chau, D. Hughes, A. Mehta, T. Foltynie, J.M. Cooper, A.Y. Abramov, and M. Gegg Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells Brain 137 2014 1481 1495
111. A. McNeill, G. Roberti, G. Lascaratos, D. Hughes, A. Mehta, D.F. Garway-Heath, and A.H. Schapira Retinal thinning in Gaucher disease patients and carriers: results of a pilot study Mol. Genet. Metabol. 109 2013 221 223
112. A. McNeill, R.-M. Wu, K.-Y. Tzen, P.C. Aguiar, J.M. Arbelo, P. Barone, K. Bhatia, O. Barsottini, V. Bonifati, and S. Bostantjopoulou Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis PLoS One 8 2013 e69190
113. B. Medrano-Engay, P. Irun, J. Gervas-Arruga, M. Andrade-Campos, V. Andreu, P. Alfonso, M. Pocovi, and P. Giraldo Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease Blood Cells Mol. Dis. 53 2014 171 175
114. V. Metta, K. Logishetty, P. Martinez-Martin, H.M. Gage, P. Schartau, T. Kaluarachchi, A. Martin, P. Odin, P. Barone, and F. Stocchi The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validation project Parkinson's Dis. 2011 2011 125271
115. M.M. Mielke, W. Maetzler, N.J. Haughey, V.V. Bandaru, R. Savica, C. Deuschle, T. Gasser, A.-K. Hauser, S. Gräber-Sultan, and E. Schleicher Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study PLoS One 8 2013 e73094
116. P.K. Mistry, J. Liu, L. Sun, W.-L. Chuang, T. Yuen, R. Yang, P. Lu, K. Zhang, J. Li, and J. Keutzer Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease Proc. Natl. Acad. Sci. 111 2014 4934 4939
117. J. Mitsui, T. Matsukawa, H. Sasaki, I. Yabe, M. Matsushima, A. Dürr, A. Brice, H. Takashima, A. Kikuchi, and M. Aoki Variants associated with Gaucher disease in multiple system atrophy Ann. Clin. Transl. Neurol. 2 2015 417 426
118. T. Moreno-Ramos, J. Benito-León, A. Villarejo, and F. Bermejo-Pareja Retinal nerve fiber layer thinning in dementia associated with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease J. Alzheimer's Dis. JAD 34 2012 659 664
119. S. Moussaud, D.R. Jones, E.L. Moussaud-Lamodière, M. Delenclos, O.A. Ross, and P.J. McLean Alpha-synuclein and tau: teammates in neurodegeneration? Mol. Neurodegener. 9 2014 43
120. K.E. Murphy, A.M. Gysbers, S.K. Abbott, N. Tayebi, W.S. Kim, E. Sidransky, A. Cooper, B. Garner, and G.M. Halliday Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease Brain 137 2014 834 848
121. M.A. Nalls, R. Duran, G. Lopez, M. Kurzawa-Akanbi, I.G. McKeith, P.F. Chinnery, C.M. Morris, J. Theuns, D. Crosiers, and P. Cras A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies JAMA Neurol. 70 2013 727 735
122. A. Narita, K. Shirai, N. Kubota, R. Takayama, Y. Takahashi, T. Onuki, C. Numakura, M. Kato, Y. Hamada, and N. Sakai Abnormal pupillary light reflex with chromatic pupillometry in Gaucher disease Ann. Clin. Transl. Neurol. 1 2014 135 140
123. K. Nishioka, O.A. Ross, K. Ishii, J.M. Kachergus, K. Ishiwata, M. Kitagawa, S. Kono, T. Obi, K. Mizoguchi, and Y. Inoue Expanding the clinical phenotype of SNCA duplication carriers Mov. Disord. 24 2009 1811 1819
124. C. Noelker, L. Lu, M. Höllerhage, F. Vulinovic, A. Sturn, R. Roscher, G.U. Höglinger, E.C. Hirsch, W.H. Oertel, and D. Alvarez-Fischer Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease J. Neurol. Sci. 356 2015 129 136
125. E. Nuzhnyi, A. Emelyanov, T. Boukina, T. Usenko, A. Yakimovskii, E. Zakharova, and S. Pchelina Plasma oligomeric Alpha-Synuclein is associated with glucocerebrosidase activity in gaucher disease Mov. Disord. 30 2015 989 991
126. M.K. Pandey, N.A. Jabre, Y.-H. Xu, W. Zhang, K.D. Setchell, and G.A. Grabowski Gaucher disease: chemotactic factors and immunological cell invasion in a mouse model Mol. Genet. Metabol. 111 2014 163 171
127. N. Pankratz, G.W. Beecham, A.L. DeStefano, T.M. Dawson, K.F. Doheny, S.A. Factor, T.H. Hamza, A.Y. Hung, B.T. Hyman, and A.J. Ivinson Meta-analysis of Parkinson's Disease: Identification of a novel locus, RIT2 Ann. Neurol. 71 2012 370 384
128. G. Parenti, G. Andria, and K.J. Valenzano Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders Mol. Ther. 23 2015 1138 1148
129. T. Payne, M. Keatinge, M. Da Costa, and O. Bandmann MPP+ in a zebrafish model of glucocerebrosidase 1 deficiency J. Neurol., Neurosurg. Psychiatry 86 2015 e4-e4
130. R.M. Poole Eliglustat: first global approval Drugs 74 2014 1829 1836
131. T. Pulkes, L. Choubtum, S. Chitphuk, A. Thakkinstian, S. Pongpakdee, K. Kulkantrakorn, S. Hanchaiphiboolkul, S. Tiamkao, and P. Boonkongchuen Glucocerebrosidase mutations in Thai patients with Parkinson's disease Park. Relat. Disord. 20 2014 986 991
132. A.A. Rahim, A.M. Wong, K. Hoefer, S.M. Buckley, C.N. Mattar, S.H. Cheng, J.K. Chan, J.D. Cooper, and S.N. Waddington Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system FASEB J. 25 2011 3505 3518
133. C. Ran, M.O. Westerlund, M. Ramezani, S. Gellhaar, F. Xiang, C. Fardell, H. Nissbrandt, P. Soderkvist, T. Willows, and T. Willows Glucocerebrosidase (GBA) mutations in Parkinson's disease in Sweden and tissue expression of GBA mRNA Mov. Disord. 29 2014 S60-S60
134. D. Reczek, M. Schwake, J. Schröder, H. Hughes, J. Blanz, X. Jin, W. Brondyk, S. Van Patten, T. Edmunds, and P. Saftig LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of β-glucocerebrosidase Cell 131 2007 770 783
135. F. Richter, S.M. Fleming, M. Watson, V. Lemesre, L. Pellegrino, B. Ranes, C. Zhu, F. Mortazavi, C.K. Mulligan, and P.C. Sioshansi A GCase chaperone improves motor function in a mouse model of synucleinopathy Neurotherapeutics 11 2014 840 856
136. E.M. Rocha, G.A. Smith, E. Park, H. Cao, E. Brown, P. Hallett, and O. Isacson Progressive decline of glucocerebrosidase in aging and Parkinson's disease Ann. Clin. Transl. Neurol. 2 2015 433 438
137. E.M. Rocha, G.A. Smith, E. Park, H. Cao, E. Brown, M.A. Hayes, J. Beagan, J.R. McLean, S.C. Izen, and E. Perez-Torres Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons Neurobiol. Dis. 82 2015 495 503
138. I. Ron, and M. Horowitz ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity Hum. Mol. Genet. 14 2005 2387 2398
139. I. Ron, D. Rapaport, and M. Horowitz Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease Hum. Mol. Genet. 19 2010 3771 3781
140. B. Rosenbloom, M. Balwani, J.M. Bronstein, E. Kolodny, S. Sathe, A.R. Gwosdow, J.S. Taylor, J.A. Cole, A. Zimran, and N.J. Weinreb The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol. Dis. 46 2011 95 102
141. M. Rothaug, F. Zunke, J.R. Mazzulli, M. Schweizer, H. Altmeppen, R. Lüllmann-Rauch, W.W. Kallemeijn, P. Gaspar, J.M. Aerts, and M. Glatzel LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance Proc. Natl. Acad. Sci. 111 2014 15573 15578
142. N. Samuels, D. Elstein, E. Lebel, A. Zimran, and M. Oberbaum Acupuncture for symptoms of Gaucher disease Complementary Ther. Med. 20 2012 131 134
143. S.P. Sardi, J. Clarke, C. Viel, M. Chan, T.J. Tamsett, C.M. Treleaven, J. Bu, L. Sweet, M.A. Passini, and J.C. Dodge Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies Proc. Natl. Acad. Sci. 110 2013 3537 3542
144. C. Sato, A. Morgan, A.E. Lang, S. Salehi-Rad, T. Kawarai, Y. Meng, P.N. Ray, L.A. Farrer, S. George-Hyslop, and E. Rogaeva Analysis of the glucocerebrosidase gene in Parkinson's disease Mov. Disord. 20 2005 367 370
145. A.H. Schapira, and M.E. Gegg Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease Proc. Natl. Acad. Sci. 110 2013 3214 3215
146. C.H. Schenck, B.F. Boeve, and M.W. Mahowald Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series Sleep. Med. 14 2013 744 748
147. R. Schiffmann, E.J. FitzGibbon, C. Harris, C. DeVile, E.H. Davies, L. Abel, I.N. Van Schaik, W.S. Benko, M. Timmons, and M. Ries Randomized, controlled trial of miglustat in Gaucher's disease type 3 Ann. Neurol. 64 2008 514 522
148. S.P. Schmid, E.D. Schleicher, A. Cegan, C. Deuschle, S. Baur, A.K. Hauser, M. Synofzik, K. Srulijes, K. Brockmann, and D. Berg Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease Mov. Disord. 27 2012 288 293
149. D.C. Schöndorf, M. Aureli, F.E. McAllister, C.J. Hindley, F. Mayer, B. Schmid, S.P. Sardi, M. Valsecchi, S. Hoffmann, and L.K. Schwarz iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis Nat. Commun. 5 2014 4028
150. B. Segarane, A. Li, R. Paudel, S. Scholz, J. Neumann, A. Lees, T. Revesz, J. Hardy, C. Mathias, and N. Wood Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy Neurology 72 2009 1185 1186
151. S.-F. Seidova, K. Kotliar, F. Foerger, M. Klopfer, and I. Lanzl Functional retinal changes in Gaucher disease Doc. Ophthalmol. 118 2009 151 154
152. E. Shemesh, L. Deroma, B. Bembi, P. Deegan, C. Hollak, N.J. Weinreb, and T.M. Cox Enzyme replacement and substrate reduction therapy for Gaucher disease Cochrane Libr. 2015
153. J. Sian-Hülsmann, S. Mandel, M.B. Youdim, and P. Riederer The relevance of iron in the pathogenesis of Parkinson's disease J. Neurochem. 118 2011 939 957
154. E. Sidransky, and G. Lopez The link between the GBA gene and parkinsonism Lancet Neurol. 11 2012 986 998
155. E. Sidransky, M.A. Nalls, J.O. Aasly, J. Aharon-Peretz, G. Annesi, E.R. Barbosa, A. Bar-Shira, D. Berg, J. Bras, and A. Brice Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease N. Engl. J. Med. 361 2009 1651 1661
156. M. Siebert, W. Westbroek, Y.-C. Chen, N. Moaven, Y. Li, M.L. Saraiva-Pereira, S. Martin, and E. Sidransky MiRNAs and glucocerebrosidase: lessons from miRNA mimic screening Mol. Genet. Metabol. 111 2014 S98
157. M. Siebert, W. Westbroek, Y.-C. Chen, N. Moaven, Y. Li, A. Velayati, M.L. Saraiva-Pereira, S.E. Martin, and E. Sidransky Identification of miRNAs that modulate glucocerebrosidase activity in Gaucher disease cells RNA Biol. 11 2014 1291 1300
158. S. Simon-Tov, T. Dinur, N. Giladi, A. Bar-Shira, M. Zelis, A. Zimran, and D. Elstein Color discrimination in patients with gaucher disease and parkinson disease J. Parkinson's Dis. 5 2015 525 531
159. M.G. Spillantini, R.A. Crowther, R. Jakes, M. Hasegawa, and M. Goedert α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies Proc. Natl. Acad. Sci. 95 1998 6469 6473
160. K. Srulijes, A.K. Hauser, I. Guella, R. Asselta, K. Brockmann, C. Schulte, G. Solda, R. Cilia, W. Maetzler, and L. Schols No association of GBA mutations and multiple system atrophy Eur. J. Neurol. 20 2013 e61 e62
161. R.A. Steet, S. Chung, B. Wustman, A. Powe, H. Do, and S.A. Kornfeld The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanisms Proc. Natl. Acad. Sci. 103 2006 13813 13818
162. Q.-y. Sun, J.-f. Guo, W.-w. Han, X. Zuo, L. Wang, L.-y. Yao, Q. Pan, K. Xia, X.-x. Yan, and B.-s. Tang Genetic association study of glucocerebrosidase gene L444P mutation in essential tremor and multiple system atrophy in mainland China J. Clin. Neurosci. 20 2013 217 219
163. Y. Sun, J. Florer, C.N. Mayhew, Z. Jia, Z. Zhao, K. Xu, H. Ran, B. Liou, W. Zhang, and K.D. Setchell Properties of neurons derived from induced pluripotent stem cells of gaucher disease type 2 patient fibroblasts: potential role in neuropathology PLoS One 10 2015 e0118771
164. D.J. Surmeier, J.N. Guzman, and J. Sanchez-Padilla Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease Cell Calcium 47 2010 175 182
165. M. Suzuki, N. Fujikake, T. Takeuchi, A. Kohyama-Koganeya, K. Nakajima, Y. Hirabayashi, K. Wada, and Y. Nagai Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant α-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease Hum. Mol. Genet. 24 2015 6675 6686
166. M.-S. Tan, J.-T. Yu, and L. Tan Bridging integrator 1 (BIN1): form, function, and Alzheimer's disease Trends Mol. Med. 19 2013 594 603
167. Y.L. Tan, J.C. Genereux, S. Pankow, J.M. Aerts, J.R. Yates, and J.W. Kelly ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease Chem. Biol. 21 2014 967 976
168. Y. Terao, H. Fukuda, Y. Ugawa, and O. Hikosaka New perspectives on the pathophysiology of Parkinson's disease as assessed by saccade performance: a clinical review Clin. Neurophysiol. 124 2013 1491 1506
169. G. Tettamanti, R. Bassi, P. Viani, and L. Riboni Salvage pathways in glycosphingolipid metabolism Biochimie 85 2003 423 437
170. R. Török, D. Zádori, N. Török, É. Csility, L. Vécsei, and P. Klivényi An assessment of the frequency of mutations in the GBA and VPS35 genes in Hungarian patients with sporadic Parkinson's disease Neurosci. Lett. 610 2016 135 138
171. E.E. Tsironi, A. Dastiridou, A. Katsanos, E. Dardiotis, S. Veliki, G. Patramani, F. Zacharaki, S. Ralli, and G.M. Hadjigeorgiou Perimetric and retinal nerve fiber layer findings in patients with Parkinson's disease BMC Ophthalmol. 12 2012 54
172. D. Tsuang, J.B. Leverenz, O.L. Lopez, R.L. Hamilton, D.A. Bennett, J.A. Schneider, A.S. Buchman, E.B. Larson, P.K. Crane, and J.A. Kaye GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology Neurology 79 2012 1944 1950
173. T. Tsunemi, K. Hamada, and D. Krainc ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein J. Neurosci. 34 2014 15281 15287
174. T. Tsunemi, and D. Krainc Zn2+ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation Hum. Mol. Genet. 23 2014 2791 2801
175. N. Uemura, M. Koike, S. Ansai, M. Kinoshita, T. Ishikawa-Fujiwara, H. Matsui, K. Naruse, N. Sakamoto, Y. Uchiyama, and T. Todo Viable neuronopathic gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein PLoS Genet. 11 2015 e1005065-e1005065
176. F. Vairo, F. Sperb-Ludwig, M. Wilke, K. Michellin-Tirelli, C. Netto, E.C. Neto, and I.V.D. Schwartz Brain-derived neurotrophic factor expression increases after enzyme replacement therapy in Gaucher disease J. Neuroimmunol. 278 2015 190 193
177. A. Velayati, J. DePaolo, N. Gupta, J.H. Choi, N. Moaven, W. Westbroek, O. Goker-Alpan, E. Goldin, B.K. Stubblefield, and E. Kolodny A mutation in SCARB2 is a modifier in Gaucher disease Hum. Mutat. 32 2011 1232 1238
178. E.B. Vitner, R. Salomon, T. Farfel-Becker, A. Meshcheriakova, M. Ali, A.D. Klein, F.M. Platt, T.M. Cox, and A.H. Futerman RIPK3 as a potential therapeutic target for Gaucher's disease Nat. Med. 20 2014 204 208
179. E.B. Vitner, A. Vardi, T.M. Cox, and A.H. Futerman Emerging therapeutic targets for Gaucher disease Expert Opin. Ther. Targets 19 2015 321 334
180. S. Waldherr, I. Mata, M. Cornejo-Olivas, L. Torres, P. Mazzetti, C. Cosentino, C. Velez-Pardo, M. Jimenez-Del-Rio, F. Lopera-Restrepo, and V. Tumas Analysis of the GBA gene in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD) Mov. Disord. 29 2014 S64-S64
181. C. Wang, Y. Cai, Z. Gu, J. Ma, Z. Zheng, B.-S. Tang, Y. Xu, Y. Zhou, T. Feng, and T. Wang Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals Neurobiol. Aging 35 2014 721 725
182. N.J. Weinreb, J. Goldblatt, J. Villalobos, J. Charrow, J.A. Cole, M. Kerstenetzky, S. Vom Dahl, and C. Hollak Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment J. Inherit. Metabol. Dis. 36 2013 543 553
183. G.K. Wenning, N. Stefanova, K.A. Jellinger, W. Poewe, and M.G. Schlossmacher Multiple system atrophy: a primary oligodendrogliopathy Ann. Neurol. 64 2008 239 246
184. S.E. Winder-Rhodes, J.R. Evans, M. Ban, S.L. Mason, C.H. Williams-Gray, T. Foltynie, R. Duran, N.E. Mencacci, S.J. Sawcer, and R.A. Barker Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort Brain 136 2013 392 399
185. C.M. Woodard, B.A. Campos, S.-H. Kuo, M.J. Nirenberg, M.W. Nestor, M. Zimmer, E.V. Mosharov, D. Sulzer, H. Zhou, and D. Paull Ipsc-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease Cell Rep. 9 2014 1173 1182
186. Y.-h. Xu, K. Xu, Y. Sun, B. Liou, B. Quinn, R.-h. Li, L. Xue, W. Zhang, K.D. Setchell, and D. Witte Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice Hum. Mol. Genet. 2014 ddu105
187. Y. Xu, Y. Sun, H. Ran, B. Quinn, D. Witte, and G. Grabowski Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models Mol. Genet. Metabol. 102 2011 436 447
188. C. Yang, S. Rahimpour, J. Lu, K. Pacak, B. Ikejiri, R.O. Brady, and Z. Zhuang Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones Proc. Natl. Acad. Sci. 110 2013 966 971
189. C. Yang, C.L. Swallows, C. Zhang, J. Lu, H. Xiao, R.O. Brady, and Z. Zhuang Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones Proc. Natl. Acad. Sci. 111 2014 249 254
190. C. Yang, H. Wang, D. Zhu, C.S. Hong, P. Dmitriev, C. Zhang, Y. Li, B. Ikejiri, R.O. Brady, and Z. Zhuang Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation Proc. Natl. Acad. Sci. 112 2015 1137 1142
191. T.L. Yap, J.M. Gruschus, A. Velayati, E. Sidransky, and J.C. Lee Saposin C Protects glucocerebrosidase against α-synuclein inhibition Biochemistry 52 2013 7161 7163
192. T.L. Yap, Z. Jiang, F. Heinrich, J.M. Gruschus, C.M. Pfefferkorn, M. Barros, J.E. Curtis, E. Sidransky, and J.C. Lee Structural features of membrane-bound glucocerebrosidase and α-synuclein probed by neutron reflectometry and fluorescence spectroscopy J. Biol. Chem. 290 2015 744 754
193. T.L. Yap, A. Velayati, E. Sidransky, and J.C. Lee Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity Mol. Genet. Metabol. 108 2013 56 64
194. Z. Yu, A.R. Sawkar, and J.W. Kelly Pharmacologic chaperoning as a strategy to treat Gaucher disease FEBS J. 274 2007 4944 4950
195. Z. Yu, T. Wang, J. Xu, W. Wang, G. Wang, C. Chen, L. Zheng, L. Pan, D. Gong, and X. Li Mutations in the glucocerebrosidase gene are responsible for Chinese patients with Parkinson's disease J. Hum. Genet. 60 2015 85 90
196. Y. Zhao, J. Ren, S. Padilla-Parra, E.E. Fry, and D.I. Stuart Lysosome sorting of β-glucocerebrosidase by LIMP-2 is targeted by the mannose 6-phosphate receptor Nat. Commun. 5 2014 4321
197. A. Zimran, G. Altarescu, and D. Elstein Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease Blood Cells Mol. Dis. 50 2013 134 137
198. A. Zimran, and D. Elstein Management of Gaucher disease: enzyme replacement therapy Pediatr. Endocrinol. Rev. PER 12 2014 82 87
199. H. Zigdon, A. Savidor, Y. Levin, A. Meshcheriakova, R. Schiffmann, and A.H. Futerman Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of gaucher disease PLoS One 10 2015 e0120194
200. Y.C. Zion, and H. Rosenbaum Quality of life and Gaucher disease Mol. Genet. Metabol. 114 2015 S30
201. N. Zokaei, A. McNeill, C. Proukakis, M. Beavan, P. Jarman, P. Korlipara, D. Hughes, A. Mehta, M.T. Hu, and A.H. Schapira Visual short-term memory deficits associated with GBA mutation and Parkinson's disease Brain 137 2014 2303 2311